
AAPG Stock Forecast & Price Target
AAPG Analyst Ratings
Bulls say
Ascentage Pharma Group has demonstrated significant commercial success with olverembatinib, achieving RMB 217.4 million (approximately US$30.3 million) in sales during the first half of 2025, reflecting a robust year-over-year growth of about 93%. The company's strategic expansion into approximately 867 hospitals and the onboarding of additional direct-to-patient pharmacies and hospitals have enhanced its market penetration, particularly in Tier 1 and 2 oncology centers. Furthermore, the favorable market dynamics for Chinese biotech, underscored by a 58% year-to-date performance of a China Biotech ETF, suggest a positive investment climate, potentially benefiting Ascentage Pharma's trajectory in the biotech sector.
Bears say
Ascentage Pharma Group's stock outlook is negatively impacted by persistent pressure from volume-based procurement programs, which, while exempting innovative therapies during early commercialization, may still contribute to margin erosion and slowing revenue growth due to aggressive NRDL repricing cycles. Additionally, failures to meet primary endpoints in pivotal studies and declining response rates for its therapies hinder its global expansion potential, particularly affecting its competitive positioning in a less competitive landscape following setbacks in clinical trials. Furthermore, slower adoption rates in China for Olverembatinib, coupled with global studies that do not adequately differentiate the drug from existing treatments, pose significant challenges to the company's growth and overall financial health.
This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.
AAPG Analyst Forecast & Price Prediction
Start investing in AAPG
Order type
Buy in
Order amount
Est. shares
0 shares